Repotrectinib Expands Treatment Options for Lung Cancers with ROS1 Fusions
Cancer Currents: An NCI Cancer Research Blog,
The results of the clinical trial that led to FDA’s 2023 approval of repotrectinib (Augtyro) for lung cancers with ROS1 fusions…
Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations
Overview of attention for article published in Molecular Cancer Therapeutics, October 2021
Altmetric Badge
About this Attention Score
-
In the top 5% of all research outputs scored by Altmetric
-
Among the highest-scoring outputs from this source (#39 of 5,232)
-
High Attention Score compared to outputs of the same age (98th percentile)
-
High Attention Score compared to outputs of the same age and source (93rd percentile)
Readers on
- mendeley
- 47 Mendeley